• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

朝向人类细胞核苷转运的分子基础。

Toward a Molecular Basis of Cellular Nucleoside Transport in Humans.

机构信息

Department of Biochemistry, Duke University Medical Center, 303 Research Drive, Durham, North Carolina 27710, United States.

出版信息

Chem Rev. 2021 May 12;121(9):5336-5358. doi: 10.1021/acs.chemrev.0c00644. Epub 2020 Nov 24.

DOI:10.1021/acs.chemrev.0c00644
PMID:33232132
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10032034/
Abstract

Nucleosides play central roles in all facets of life, from metabolism to cellular signaling. Because of their physiochemical properties, nucleosides are lipid bilayer impermeable and thus rely on dedicated transport systems to cross biological membranes. In humans, two unrelated protein families mediate nucleoside membrane transport: the concentrative and equilibrative nucleoside transporter families. The objective of this review is to provide a broad outlook on the current status of nucleoside transport research. We will discuss the role played by nucleoside transporters in human health and disease, with emphasis placed on recent structural advancements that have revealed detailed molecular principles of these important cellular transport systems and exploitable pharmacological features.

摘要

核苷在生命的各个方面都起着核心作用,从新陈代谢到细胞信号传递。由于其理化性质,核苷不易穿透脂质双层,因此依赖于专门的转运系统来穿过生物膜。在人类中,有两个不相关的蛋白家族介导核苷的膜转运:协同转运体和平衡转运体家族。本文综述的目的是提供核苷转运研究的现状概述。我们将讨论核苷转运体在人类健康和疾病中的作用,重点介绍最近的结构进展,这些进展揭示了这些重要细胞转运系统的详细分子原理和可利用的药理学特征。

相似文献

1
Toward a Molecular Basis of Cellular Nucleoside Transport in Humans.朝向人类细胞核苷转运的分子基础。
Chem Rev. 2021 May 12;121(9):5336-5358. doi: 10.1021/acs.chemrev.0c00644. Epub 2020 Nov 24.
2
Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters.平衡型和浓缩型核苷转运体的生化及结构特性研究的最新进展
Acta Biochim Pol. 2005;52(4):749-58. Epub 2005 Oct 25.
3
Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney.核苷转运体在肾脏中核苷类似物的处置和靶向作用
Eur J Pharmacol. 2003 Oct 31;479(1-3):269-81. doi: 10.1016/j.ejphar.2003.08.076.
4
Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å.霍乱弧菌高亲和性核苷转运蛋白的 2.4Å 晶体结构。
Nature. 2012 Mar 11;483(7390):489-93. doi: 10.1038/nature10882.
5
Renal nucleoside transporters: physiological and clinical implications.肾脏核苷转运体:生理及临床意义
Biochem Cell Biol. 2006 Dec;84(6):844-58. doi: 10.1139/o06-198.
6
Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.转运体转运核苷和结构类似药物:底物识别的结构要求。
Med Res Rev. 2012 Mar;32(2):428-57. doi: 10.1002/med.20221. Epub 2011 Feb 1.
7
Use of molecular modelling to probe the mechanism of the nucleoside transporter NupG.利用分子建模探究核苷转运蛋白NupG的机制。
Mol Membr Biol. 2013 Mar;30(2):114-28. doi: 10.3109/09687688.2012.748939. Epub 2012 Dec 21.
8
Mammalian nucleoside transporters.哺乳动物核苷转运体。
Curr Drug Metab. 2004 Feb;5(1):63-84. doi: 10.2174/1389200043489162.
9
Molecular biology of nucleoside transporters and their distributions and functions in the brain.核苷转运体的分子生物学及其在脑内的分布与功能。
Curr Top Med Chem. 2011;11(8):948-72. doi: 10.2174/156802611795347582.
10
Cell entry and export of nucleoside analogues.核苷类似物的细胞内摄入与排出
Virus Res. 2005 Feb;107(2):151-64. doi: 10.1016/j.virusres.2004.11.005.

引用本文的文献

1
Ciclopirox suppresses poxvirus replication by targeting iron metabolism.环吡酮通过靶向铁代谢来抑制痘病毒复制。
bioRxiv. 2025 Jul 24:2025.07.24.666650. doi: 10.1101/2025.07.24.666650.
2
Landscape of targets within nucleoside metabolism for the modification of immune responses.用于调节免疫反应的核苷代谢中的靶点格局。
Front Oncol. 2025 May 30;15:1483769. doi: 10.3389/fonc.2025.1483769. eCollection 2025.
3
Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients.突变型p53与肝内胆管癌患者人平衡核苷转运体1上调及对吉西他滨辅助治疗的更好反应相关。
Int J Mol Sci. 2025 May 30;26(11):5259. doi: 10.3390/ijms26115259.
4
Mechanistic insights into proton-coupled substrate translocation of nucleoside proton symporters.核苷质子同向转运体质子偶联底物转运的机制洞察。
J Biol Chem. 2025 Apr;301(4):108357. doi: 10.1016/j.jbc.2025.108357. Epub 2025 Feb 25.
5
Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief.用于缓解疼痛的平衡核苷转运体1型抑制剂的设计。
Nat Commun. 2024 Dec 30;15(1):10738. doi: 10.1038/s41467-024-54914-7.
6
Regulation of and challenges in targeting NAD metabolism.靶向 NAD 代谢的调控及挑战。
Nat Rev Mol Cell Biol. 2024 Oct;25(10):822-840. doi: 10.1038/s41580-024-00752-w. Epub 2024 Jul 18.
7
Elucidation of the Gemcitabine Transporters of K-12 and Gamma-Proteobacteria Linked to Gemcitabine-Related Chemoresistance.阐明与吉西他滨相关化疗耐药性相关的 K-12 和γ-变形菌的吉西他滨转运蛋白。
Int J Mol Sci. 2024 Jun 27;25(13):7012. doi: 10.3390/ijms25137012.
8
Exploring novel dilazep derivatives as hENT1 inhibitors and potentially covalent molecular tools.探索新型双嘧达莫衍生物作为人ENT1抑制剂和潜在的共价分子工具。
Purinergic Signal. 2025 Apr;21(2):289-316. doi: 10.1007/s11302-024-10026-x. Epub 2024 Jun 15.
9
Adenine-induced animal model of chronic kidney disease: current applications and future perspectives.腺嘌呤诱导的慢性肾脏病动物模型:当前应用及未来展望。
Ren Fail. 2024 Dec;46(1):2336128. doi: 10.1080/0886022X.2024.2336128. Epub 2024 Apr 4.
10
Antiviral drug recognition and elevator-type transport motions of CNT3.抗病毒药物识别与 CNT3 的电梯式输运运动。
Nat Chem Biol. 2024 Sep;20(9):1144-1153. doi: 10.1038/s41589-024-01559-8. Epub 2024 Feb 28.

本文引用的文献

1
Cryo-EM structure of the human concentrative nucleoside transporter CNT3.人源核苷转运蛋白 CNT3 的冷冻电镜结构
PLoS Biol. 2020 Aug 10;18(8):e3000790. doi: 10.1371/journal.pbio.3000790. eCollection 2020 Aug.
2
Elevator-type mechanisms of membrane transport.膜转运的电梯式机制。
Biochem Soc Trans. 2020 Jun 30;48(3):1227-1241. doi: 10.1042/BST20200290.
3
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
4
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
5
Expansion of the Major Facilitator Superfamily (MFS) to include novel transporters as well as transmembrane-acting enzymes.将主要易化子超家族(MFS)扩展到包括新型转运蛋白以及跨膜作用的酶。
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183277. doi: 10.1016/j.bbamem.2020.183277. Epub 2020 Mar 20.
6
A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs.SLC 跨膜转运蛋白在细胞毒性药物耐药中的广泛作用。
Nat Chem Biol. 2020 Apr;16(4):469-478. doi: 10.1038/s41589-020-0483-3. Epub 2020 Mar 9.
7
Autoinflammation in addition to combined immunodeficiency: SLC29A3 gene defect.除联合免疫缺陷外的自身炎症:SLC29A3 基因突变。
Mol Immunol. 2020 May;121:28-37. doi: 10.1016/j.molimm.2020.02.014. Epub 2020 Mar 6.
8
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒(2019 - 新冠病毒)。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
9
The molecular basis for sugar import in malaria parasites.疟原虫中糖摄取的分子基础。
Nature. 2020 Feb;578(7794):321-325. doi: 10.1038/s41586-020-1963-z. Epub 2020 Jan 29.
10
Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.代谢调节剂筛选揭示了核苷酸代谢中蛋白激酶抑制剂的次要靶点。
Cell Chem Biol. 2020 Feb 20;27(2):197-205.e6. doi: 10.1016/j.chembiol.2019.10.012. Epub 2019 Nov 13.